|

Finerenone Clinical Trials

6 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Angiotensin II Receptor Blockers, Firialta, Kerendia

Pipeline

Phase 3: 4Phase 4: 1

Top Sponsors

  • Colorado Prevention Center3
  • Steno Diabetes Center Copenhagen1
  • Second Affiliated Hospital of Soochow University1
  • Chinese University of Hong Kong1

Indications

Other3 trials

Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Phase 3
Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
Phase 4

Fairhope, Alabama2 trials

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

CON-10004 Fairhope, AL Investigational Site

Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

FIN-10004 Fairhope, AL Investigational Site

Phase 3

Birmingham, Alabama1 trial

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Birmingham, AL Investigative Site 10012

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.